12.15.15
Washington-based Chase Pharmaceuticals has appointed Douglas Ingram as its new chief executive officer to replace John Siebert, who will continue working with the company in an advisory capacity.
Mr. Ingram brings to the role nearly 20 years of experience in biotech, pharmaceutical and medical devices leadership. Prior to serving as president of Allergan, Ingram directed the company's operations in Europe, the Middle East and Africa and was responsible for various aspects of its global organization including regulatory affairs and external communications.
As chief executive, Mr. Ingram will focus on the direction of Chase Pharmaceuticals' development and commercialization of improved treatments for neurodegenerative disorders, in particular its current work on symptomatic treatment of Alzheimer's disease.
“Doug has a proven track record of disruptive approaches, building strong teams and delivering above-market performance,” said Greg Parekh, chairman, Chase Pharmaceuticals. “I am confident that Doug will successfully develop Chase to its fullest potential.”
Mr. Ingram brings to the role nearly 20 years of experience in biotech, pharmaceutical and medical devices leadership. Prior to serving as president of Allergan, Ingram directed the company's operations in Europe, the Middle East and Africa and was responsible for various aspects of its global organization including regulatory affairs and external communications.
As chief executive, Mr. Ingram will focus on the direction of Chase Pharmaceuticals' development and commercialization of improved treatments for neurodegenerative disorders, in particular its current work on symptomatic treatment of Alzheimer's disease.
“Doug has a proven track record of disruptive approaches, building strong teams and delivering above-market performance,” said Greg Parekh, chairman, Chase Pharmaceuticals. “I am confident that Doug will successfully develop Chase to its fullest potential.”